Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes
Abstract
The in vitro antifungal activity of different statins and the combinations of the two most effective ones (fluvastatin and rosuvastatin) with amphotericin B were investigated in this study on 6 fungal isolates representing 4 clinically important genera, namely Absidia, Rhizomucor, Rhizopus and Syncephalastrum . The antifungal effects of statins revealed substantial differences. The synthetic statins proved to be more effective than the fungal metabolites. All investigated strains proved to be sensitive to fluvastatin. Fluvastatin and rosuvastatin acted synergistically and additively with amphotericin B in inhibiting the fungal growth in clinically available concentration ranges. Results suggest that statins combined with amphotericin B have a therapeutic potential against fungal infections caused by Zygomycetes species.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Natural statins (e.g. SIM and LOV) mainly exert antifungal activity in their active metabolite forms (hydrolysis of the lactone ring at pH 10) and are less effective as pro-drugs.
“The natural statins (e.g.SIM and LOV) mainly effect their antifungal activity in their active metabolite forms (hydrolysis of the lactone ring at pH 10), and they proved to be less effective as pro-drugs [18,19] .”
From Statins as antifungal agents (2011) · cites this paper as [19]
Generally, synthetic statins are more effective than natural statins.
“Generally, the synthetic statins are more effective than the natural ones [18,19] .”
From Statins as antifungal agents (2011) · cites this paper as [19]
The inhibition activity of statins on the growth of filamentous fungi was revealed in several zygomycetous and ascomycetous fungal species.
“The inhibition activity of statins on the growth of filamentous fungi was revealed in the cases of several zygo- [18,19,28,[31][32][33][34][35] and ascomycetous fungal species [18,25,28,29,36,37] .”
From Statins as antifungal agents (2011) · cites this paper as [19]
Synergistic and additive interactions were revealed between statins and antifungal agents in zygomycetous fungal species.
“Synergistic and additive interactions were revealed between statins and antifungal agents in the case of zygomycetous fungal species [18,19,28,29,33] .”
From Statins as antifungal agents (2011) · cites this paper as [19]
In vitro, FLV and ROS acted synergistically and additively with AMB in inhibiting growth of Zygomycetes over clinically available concentration ranges in human serum.
“In vitro, FLV and ROS acted synergistically and additively with AMB in inhibiting the growth of fungi belonging to Zygomycetes over their clinically available concentration ranges in human serum [19] .”
From Statins as antifungal agents (2011) · cites this paper as [19]
Cites
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994 · see citing works
Ribes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236-301.2000 · Cited by 1,702 · see citing works
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
Schächter, M. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,216 · see citing works
Antibiotics in laboratory medicine
(1997) · doi:10.1016/s0732-8893(97)00063-1 · Cited by 1,036 · see citing works
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796 · see citing works
Infections due to emerging and uncommon medically important fungal pathogens
Walsh, T. J., Groll, A. H., Hiemenz, J., Fleming, R. V., Roilides, E., & Anaissie, E. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00839.x · Cited by 600 · see citing works
Prabhu, R. M., & Patel, R. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00843.x · Cited by 594 · see citing works
Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation · doi:10.1161/01.cir.0000131519.15067.1f · Cited by 578 · see citing works
Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., & McNicholas, P. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00163-06 · Cited by 491 · see citing works
Groll, A. H., Giri, N., Petraitis, V., Petraitienė, R., Candelario, M., Bacher, J., Piscitelli, S. C., & Walsh, T. J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315643 · Cited by 373 · see citing works
Zygomycosis: the re-emerging fungal infection
Chayakulkeeree, M., Ghannoum, M. A., & Perfect, J. R. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0107-1 · Cited by 371 · see citing works
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216421 · Cited by 352 · see citing works
Almyroudis, N. G., Sutton, D. A., Fothergill, A. W., Rinaldi, M. G., & Kusne, S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00452-07 · Cited by 284 · see citing works
Mechanisms of Statin-mediated Inhibition of Small G-protein Function
Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A., & Landreth, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505268200 · Cited by 235 · see citing works
Microbial natural products as a source of antifungals
Vicente, M. F., Basilio, Á., Cabello, A., & Peláez, F. (2003) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2003.00489.x · Cited by 191 · see citing works
Treatment of zygomycosis: current and new options
Rogers, T. R. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm429 · Cited by 179 · see citing works
Ghittoni, R., Patrussi, L., Pirozzi, K., Pellegrini, M., Lazzerini, P. E., Capecchi, P. L., Pasini, F. L., & Baldari, C. T. (2005) · The FASEB Journal · doi:10.1096/fj.04-2702fje · Cited by 154 · see citing works
Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients
Nucci, M. (2003) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200312000-00015 · Cited by 152 · see citing works
Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor
Kajinami, K., Takekoshi, N., & Saito, Y. (2003) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2003.tb00116.x · Cited by 136 · see citing works
Chamilos, G., Lewis, R. E., & Kontoyiannis, D. P. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.96-103.2006 · Cited by 121 · see citing works
Lorenz, R. T., & Parks, L. W. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.9.1660 · Cited by 104 · see citing works
Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia
Miida, T., Hirayama, S., & Nakamura, Y. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.253 · Cited by 97 · see citing works
Lovastatin Triggers an Apoptosis-like Cell Death Process in the FungusMucor racemosus
Roze, L. V., & Linz, J. E. (1998) · Fungal Genetics and Biology · doi:10.1006/fgbi.1998.1093 · Cited by 96 · see citing works
Activity of the Antifungal Protein from Aspergillus giganteus Against Botrytis cinerea
Moreno, A. B., Martínez‐del‐Pozo, Á., Borja, M., & Segundo, B. S. (2003) · Phytopathology · doi:10.1094/phyto.2003.93.11.1344 · Cited by 82 · see citing works
Pharmacokinetic Interactions Between Statins and Fibrates
Corsini, A., Bellosta, S., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.007 · Cited by 69 · see citing works
Sun, H., & Singh, N. (2009) · Clinical Infectious Diseases · doi:10.1086/597039 · Cited by 65 · see citing works
Antifungal pharmacotherapy for invasive mould infections
Gallagher, J. C., Ashley, E. S. D., Drew, R. H., & Perfect, J. R. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.2.147 · Cited by 46 · see citing works
Study of the toxicity of a new lipid complex formulation of amphotericin B
Larabi, M. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh025 · Cited by 43 · see citing works
In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates
Minassian, B., Huczko, E., Washo, T., et al. (2003) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2003.00755.x · Cited by 40 · see citing works
Differentiation of Rhizomucor Species on the Basis of Their Different Sensitivities to Lovastatin
Lukács, G., Papp, T., Nyilasi, I., Nagy, E., & Vágvölgyi, C. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.11.5400-5402.2004 · Cited by 40 · see citing works
Self-citationGalgóczy, L., Papp, T., Lukács, G., Leiter, Ã., Pócsi, I., & Vágvölgyi, C. (2007) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2007.00661.x · Cited by 37 · see citing works
Self-citationAn evaluation of current cholera treatment
Bhattacharya, S. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.2.141 · Cited by 37 · see citing works
Combination Antifungal Therapy: The New Frontier
Vázquez, J. A. (2007) · Future Microbiology · doi:10.2217/17460913.2.2.115 · Cited by 21 · see citing works
Lukács, G., Papp, T., Somogyvári, F., Csernetics, Á., Nyilasi, I., & Vágvölgyi, C. (2009) · Antonie van Leeuwenhoek · doi:10.1007/s10482-008-9287-2 · Cited by 19 · see citing works
Self-citation<i>In vitro</i> interaction between suramin and fluvastatin against clinically important Zygomycetes
Galgóczy, L., Papp, T., & Vágvölgyi, C. (2009) · Mycoses · doi:10.1111/j.1439-0507.2008.01634.x · Cited by 14 · see citing works
Self-citationGenotypic analysis of variability in Zygomycetes
Takó, M., & Csernetics, Á. (2005) · Acta Biologica Hungarica · doi:10.1556/abiol.56.2005.3-4.17 · Cited by 7 · see citing works
Publishers, B. S. P. B. S. (2007) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/187152907780059119 · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tavakkoli, A., Johnston, T. P., & Sahebkar, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107483 · Cited by 73 · see citing works
Galgóczy, L. (2011) · World Journal of Clinical Infectious Diseases · doi:10.5495/wjcid.v1.i1.4 · Cited by 21 · see citing works
Self-citationIs there a role for statins in fungal infections?
Bergman, P. W., & Björkhem-Bergman, L. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.856755 · Cited by 12 · see citing works
Topical statins as antifungals: a review
Khoury, D. M., Ghaoui, N., El Tayar, E., Dagher, R., El Hawa, M., Rubeiz, N., Abbas, O., & Kurban, M. (2024) · International Journal of Dermatology · doi:10.1111/ijd.17068 · Cited by 3 · see citing works
- Authors
- Galgóczy, L., Lukács, G., Nyilasi, I., Papp, T., & Vágvölgyi, C.
- Affiliations
- University of Szeged (HU)
- Venue
- Acta Biologica Hungarica
- Published
- 2010-09
- Volume
- 61
- Issue
- 3
- Pages
- 356-365
- ISSN
- 0001-5288 (ISSN-L)
- 0236-5383
- 1588-256X
- OpenAlex
- W1965076080
- Cited by
- 23
- References
- 37
- Citations by year
- 2024: 1 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 1 · 2015: 3 · 2014: 3 · 2013: 2
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Acta Biologica Hungarica (publishedVersion)
- PubMed (publishedVersion)
- Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
- Funders
- Nemzeti Kutatási és Technológiai Hivatal
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Health Sciences › Medicine › Pharmacology › Microbial Natural Products and Biosynthesis
- Keywords
- statins, fluvastatin, rosuvastatin, amphotericin B, Zygomycetes, antifungal activity, drug synergy, combination therapy, Absidia, Rhizomucor, Rhizopus, Syncephalastrum, fungal metabolites, fungal infection
- MeSH terms
- Amphotericin B, Antifungal Agents, Drug Interactions, Humans, Microbial Sensitivity Tests, Mucorales, Rhizopus, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Absidia, Zygomycosis, Rhizomucor, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
